Adverse drug reactions allergic diseases

Many chemicals (including pharmaceuticals but also environmental and occupational chemicals) are known to stimulate the immune system in a way that autoimmune diseases occur [61]. However, because of its multifactorial nature, the occurrence of autoimmune-like (including drug allergic) diseases is rare if considered on a compound-by-compound base. But, in some cases (e.g., in case of HIV or Herpes virus-infected individuals), adverse reactions occur at a higher rate [65, 66]. 

Observational studies Topical bevacizumab (5 mg/ml five times a day for 0.5-12 months) was used in 27 patients (30 eyes) with corneal neovascularization due to several causes and not responding to conventional therapy [1 ]. In five patients (five eyes) new epithelial defects developed (which could have been due to the underlying disease). There were no drug-related ocular or systemic adverse events or allergic reactions. 

A known side effect of the action of the drug being prominent or problematic because of other disease. As examples, AIDS patients have a propensity to have allergic adverse reactions. Cardiac patients may not tolerate drugs which alter the blood pressure so well since their cardiac reserve is impaired. 

Finally, CAMs can produce side effects and adverse reactions similar to conventional medications.61 Gastrointestinal disturbances (nausea, vomiting, diarrhea), headache, allergic responses, and various other reactions are possible even when CAMs are taken at appropriate doses. The type and severity of these reactions depends on many factors including the type of CAM and the individual characteristics of each patient (genetic factors, diseases, other medications, and so forth). Clearly, CAMs can produce the same types of problems as conventional medications, and consumers must be reminded that these products are actual drugs even though they may be derived from natural or nontraditional sources. 

Observational studies The short-term and long-term safety of topical bevacizumab 5 mg/ml for progressive corneal neovascularization secondary to a variety of corneal diseases and not responding to conventional anti-inflammatory treatment have been evaluated in 30 eyes of 27 patients Five patients (five eyes) developed new corneal epithelial defects. The authors warned against using bevacizumab in patients with epithelial defects and neurotrophic keratopathy. There were no allergic reactions, ocular drug-related complaints, or systemic adverse reactions. 

---